CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 Pipeline Review, H1 2018
Summary
CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 CXC chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene.
It is a receptor for the CXC chemokine CXCL12/SDF1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.
CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 pipeline Target constitutes close to 24 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.
The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 4, 3, 1 and 9 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Report covers products from therapy areas Oncology, Cardiovascular, Immunology, Infectious Disease, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Male Health, Ophthalmology and Women's Health which include indications Multiple Myeloma Kahler Disease, NonHodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Colon Cancer, Human Immunodeficiency Virus HIV Infections AIDS, Melanoma, NonSmall Cell Lung Cancer, Pancreatic Cancer, SmallCell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Aplastic Anemia, Breast Cancer, Chronic Lymphocytic Leukemia CLL, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Critical Limb Ischemia, Erectile Dysfunction, Glioblastoma Multiforme GBM, Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma HCC, Metastatic Melanoma, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, NonAlcoholic Steatohepatitis NASH, Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme GBM, Renal Cell Carcinoma, Stroke, Thrombocytopenia, Vasomotor Symptoms of Menopause Hot Flashes, Waldenstrom Macroglobulinemia, Wet Neovascular / Exudative Macular Degeneration, WHIM Syndrome Warts, Hypogammaglobulinemia and Infections and Myelokathexis.
The latest report CXC Chemokine Receptor Type 4 Pipeline Review, outlays comprehensive information on the CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4
The report reviews CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics and enlists all their major and minor projects
The report assesses CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding CXC Chemokine Receptor Type 4 FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope